{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:48:58Z","timestamp":1785808138988,"version":"3.56.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"DOI":"10.1186\/s40644-026-01062-4","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T15:03:08Z","timestamp":1780153388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["What\u2019s next for VI-RADS? Updates and future perspectives from the ACR VI-RADS steering committee"],"prefix":"10.1186","volume":"26","author":[{"given":"Sungmin","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valdair F.","family":"Muglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndon","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"de Rooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Redd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Galgano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Panebianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebert Alberto","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"1062_CR1","doi-asserted-by":"publisher","unstructured":"Filho AM, Briganti A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2025;S0302-2838(25)04864-X. https:\/\/doi.org\/10.1016\/j.eururo.2025.12.011. PubMed PMID: 41421927.","DOI":"10.1016\/j.eururo.2025.12.011"},{"key":"1062_CR2","doi-asserted-by":"publisher","unstructured":"Holzbeierlein J, Bixler BR, Buckley DI, Chang SS, Holmes RS, James AC, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO Guideline (2017; Amended 2020, 2024). J Urol. 2024;212(1):3\u201310. https:\/\/doi.org\/10.1097\/JU.0000000000003981. PubMed PMID: 38661067.","DOI":"10.1097\/JU.0000000000003981"},{"key":"1062_CR3","unstructured":"Gontero P, Birtle A, Comp\u00e9rat E, Dominguez Escrig J, Liedberg F, Mariappan P, et al. EAU guidelines on non-muscle-invasive and metastatic bladder cancer. https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer. Accessed 15 January 2026."},{"key":"1062_CR4","unstructured":"van der Heijden A, Bruins H, Carrion A, Cathomas R, Comp\u00e9rat E, Dimitropoulos K, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer. https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer. Accessed 15 January 2026."},{"key":"1062_CR5","doi-asserted-by":"publisher","unstructured":"Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018;74(3):294\u2013306. https:\/\/doi.org\/10.1016\/j.eururo.2018.04.029. PubMed PMID: 29755006; PubMed Central PMCID: PMC6690492.","DOI":"10.1016\/j.eururo.2018.04.029"},{"issue":"4","key":"1062_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41585-023-00830-2","volume":"21","author":"V Panebianco","year":"2024","unstructured":"Panebianco V, Briganti A, Boellaard TN, Catto J, Comperat E, Efstathiou J, et al. Clinical application of bladder MRI and the Vesical Imaging-Reporting and Data System. Nat Rev Urol. 2024;21(4):243\u201351. https:\/\/doi.org\/10.1038\/s41585-023-00830-2. PubMed PMID: 38036666.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"1062_CR7","doi-asserted-by":"publisher","first-page":"e233459","DOI":"10.1148\/radiol.233459","volume":"314","author":"M Pecoraro","year":"2025","unstructured":"Pecoraro M, Cipollari S, Messina E, Laschena L, Dehghanpour A, Borrelli A, et al. Multiparametric MRI for Bladder Cancer: A Practical Approach to the Clinical Application of VI-RADS. Radiology. 2025;314(3):e233459. https:\/\/doi.org\/10.1148\/radiol.233459. PubMed PMID: 40035668.","journal-title":"Radiology"},{"issue":"3","key":"1062_CR8","doi-asserted-by":"publisher","first-page":"e230149","DOI":"10.1148\/rg.230149","volume":"44","author":"P F\u00e1vero","year":"2024","unstructured":"F\u00e1vero P, Dos Santos J, Ghezzi CLA, Pedrollo IM, Cruz \u00cdR, Orozco OFG, Zapparoli M, et al. Practical Guide to VI-RADS: MRI Protocols, Lesion Characterization, and Pitfalls. Radiographics. 2024;44(3):e230149. https:\/\/doi.org\/10.1148\/rg.230149. PubMed PMID: 38421912.","journal-title":"Radiographics"},{"issue":"3","key":"1062_CR9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.euo.2020.02.007","volume":"3","author":"S Woo","year":"2020","unstructured":"Woo S, Panebianco V, Narumi Y, Del Giudice F, Muglia VF, Takeuchi M, et al. Diagnostic performance of vesical imaging reporting and data system for the prediction of muscle-invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2020;3(3):306\u201315. https:\/\/doi.org\/10.1016\/j.euo.2020.02.007. PubMed PMID: 32199915; PubMed Central PMCID: PMC7293940.","journal-title":"Eur Urol Oncol"},{"key":"1062_CR10","doi-asserted-by":"publisher","unstructured":"Del Giudice F, Flammia RS, Pecoraro M, Moschini M, D\u2019Andrea D, Messina E, et al. The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. World J Urol. 2022;40(7):1617\u201328. https:\/\/doi.org\/10.1007\/s00345-022-03969-6. PubMed PMID: 35294583; PubMed Central PMCID: PMC9237003.\u00a0","DOI":"10.1007\/s00345-022-03969-6"},{"issue":"2","key":"1062_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/20905998.2024.2442256","volume":"23","author":"AR Al-Qudimat","year":"2025","unstructured":"Al-Qudimat AR, Sabir D, Elamin M, Ching M, Altahtamouni SB, Singh K, et al. Implementing VIRADS score for image-guided assessment of muscle invasiveness in bladder cancer pre-TURBT: An updated meta-analysis. Arab J Urol. 2025;23(2):97\u2013108. https:\/\/doi.org\/10.1080\/20905998.2024.2442256. PubMed PMID: 40182574; PubMed Central PMCID: PMC11963189.","journal-title":"Arab J Urol"},{"issue":"9","key":"1062_CR12","doi-asserted-by":"publisher","first-page":"6949","DOI":"10.1007\/s00330-021-07765-5","volume":"31","author":"MI Metwally","year":"2021","unstructured":"Metwally MI, Zeed NA, Hamed EM, Elshetry ASF, Elfwakhry RM, Alaa Eldin AM, et al. The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study. Eur Radiol. 2021;31(9):6949\u201361. https:\/\/doi.org\/10.1007\/s00330-021-07765-5. PubMed PMID: 33606105.","journal-title":"Eur Radiol"},{"issue":"2","key":"1062_CR13","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/jmri.29103","volume":"60","author":"R Yu","year":"2024","unstructured":"Yu R, Cai L, Cao Q, Liu P, Gong Y, Li K, et al. Development and Validation of an MRI-Based Nomogram for Preoperative Detection of Muscle Invasion in VI-RADS 3. J Magn Reson Imaging. 2024;60(2):448\u201357. https:\/\/doi.org\/10.1002\/jmri.29103. PubMed PMID: 37902432.","journal-title":"J Magn Reson Imaging"},{"issue":"12","key":"1062_CR14","doi-asserted-by":"publisher","first-page":"8417","DOI":"10.1007\/s00330-023-09925-1","volume":"33","author":"H Ahn","year":"2023","unstructured":"Ahn H, Kim TM, Hwang SI, Lee HJ, Choe G, Hong SK, et al. Tumor contact length with bladder wall provides effective risk stratification for lesions with a VIRADS score of 2\u20133. Eur Radiol. 2023;33(12):8417\u201325. https:\/\/doi.org\/10.1007\/s00330-023-09925-1. PubMed PMID: 37438641.","journal-title":"Eur Radiol"},{"issue":"3","key":"1062_CR15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1148\/radiol.220028","volume":"304","author":"Q Cai","year":"2022","unstructured":"Cai Q, Ling J, Kong L, Huang Y, Lin Y, Wen Z, et al. Multiparametric MRI Evaluation of VI-RADS for Bladder Tumors Located at the Ureteral Orifice. Radiology. 2022;304(3):593\u20139. https:\/\/doi.org\/10.1148\/radiol.220028. PubMed PMID: 35670714.","journal-title":"Radiology"},{"issue":"12","key":"1062_CR16","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1007\/s00261-022-03669-0","volume":"47","author":"SB Jazayeri","year":"2022","unstructured":"Jazayeri SB, Dehghanbanadaki H, Hosseini M, Taghipour P, Bazargani S, Thomas D, et al. Inter-reader reliability of the vesical imaging-reporting and data system (VI-RADS) for muscle-invasive bladder cancer: a systematic review and meta-analysis. Abdom Radiol (NY). 2022;47(12):4173\u201385. https:\/\/doi.org\/10.1007\/s00261-022-03669-0. PubMed PMID: 36112202.","journal-title":"Abdom Radiol (NY)"},{"issue":"5","key":"1062_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/bju.15188","volume":"126","author":"F Del Giudice","year":"2020","unstructured":"Del Giudice F, Leonardo C, Simone G, Pecoraro M, De Berardinis E, Cipollari S, et al. Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease? BJU Int. 2020;126(5):610\u20139. https:\/\/doi.org\/10.1111\/bju.15188. PubMed PMID: 32783347.","journal-title":"BJU Int"},{"issue":"1","key":"1062_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00345-025-05666-6","volume":"43","author":"X Jiang","year":"2025","unstructured":"Jiang X, Cai L, Cao Q, Liu P, Bai R, Wu Q, et al. The role of multiparametric MRI-based VI-RADS in predicting the need for a second TURB. World J Urol. 2025;43(1):271. https:\/\/doi.org\/10.1007\/s00345-025-05666-6. PubMed PMID: 40325235.","journal-title":"World J Urol"},{"issue":"12","key":"1062_CR19","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1200\/JCO.23.02398","volume":"43","author":"RT Bryan","year":"2025","unstructured":"Bryan RT, Liu W, Pirrie SJ, Amir R, Gallagher J, Hughes AI, et al. Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial. J Clin Oncol. 2025;43(12):1417\u201328. https:\/\/doi.org\/10.1200\/JCO.23.02398. PubMed PMID: 39808757; PubMed Central PMCID: PMC12005870.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1062_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.eururo.2024.09","volume":"86","author":"V Panebianco","year":"2024","unstructured":"Panebianco V, Briganti A, Efstathiou J, Galgano S, Luk L, Muglia VF, et al. The Role of Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision of the American College of Radiology VI-RADS Steering Committee. Eur Urol. 2024;86(6):485\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.013. PubMed PMID: 39317635.","journal-title":"Eur Urol"},{"issue":"22","key":"1062_CR21","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.3390\/jcm13226955","volume":"13","author":"F Piramide","year":"2024","unstructured":"Piramide F, Sica M, Fondello G, Mesterca G, Ferrando L, Ziani N, et al. Use of Multiparametric and Biparametric Magnetic Resonance Imaging in Bladder Cancer Staging: Prospective Observational Study and Analysis of Radiologist Learning Curve. J Clin Med. 2024;13(22):6955. https:\/\/doi.org\/10.3390\/jcm13226955. PubMed PMID: 39598099; PubMed Central PMCID: PMC11595213.","journal-title":"J Clin Med"},{"issue":"1","key":"1062_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.euf.2023.08.004","volume":"10","author":"Y Arita","year":"2024","unstructured":"Arita Y, Kwee TC, Woo S, Shigeta K, Ishii R, Okawara N, et al. Biparametric versus Multiparametric Magnetic Resonance Imaging for Assessing Muscle Invasion in Bladder Urothelial Carcinoma with Variant Histology Using the Vesical Imaging-Reporting and Data System. Eur Urol Focus. 2024;10(1):131\u20138. https:\/\/doi.org\/10.1016\/j.euf.2023.08.004. PubMed PMID: 37633790.","journal-title":"Eur Urol Focus"},{"issue":"4","key":"1062_CR23","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s00261-024-04658-1","volume":"50","author":"M Takeuchi","year":"2025","unstructured":"Takeuchi M, Higaki A, Kojima Y, Ono K, Maruhisa T, Yokoyama T, et al. Diagnostic significance of peritumoral enhancement in distinguishing between muscle-invasive and non-muscle-invasive bladder cancer. Abdom Radiol (NY). 2025;50(4):1679\u201388. https:\/\/doi.org\/10.1007\/s00261-024-04658-1. PubMed PMID: 39472381.","journal-title":"Abdom Radiol (NY)"},{"issue":"13","key":"1062_CR24","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jama.2025.13722","volume":"334","author":"ABCD Ng","year":"2025","unstructured":"Ng ABCD, Asif A, Agarwal R, Panebianco V, Girometti R, Ghai S, et al. Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial. JAMA. 2025;334(13):1170\u20139. https:\/\/doi.org\/10.1001\/jama.2025.13722. PubMed PMID: 40928788; PubMed Central PMCID: PMC12423955.","journal-title":"JAMA"},{"key":"1062_CR25","doi-asserted-by":"publisher","first-page":"106862","DOI":"10.1016\/j.crad.2025.106862","volume":"84","author":"A Selvaraju","year":"2025","unstructured":"Selvaraju A, Patbamniya NK, Kumar M, Seth A, Kaushal S, Das CJ. Preoperative prediction of muscle invasion in bladder cancer in the Indian population using the Vesical Imaging-Reporting and Data System (VI-RADS) score and individual multiparametric magnetic resonance imaging (MRI) characteristics. Clin Radiol. 2025;84:106862. https:\/\/doi.org\/10.1016\/j.crad.2025.106862. PubMed PMID: 40127527.","journal-title":"Clin Radiol"},{"key":"1062_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.clinimag.2021.02.026","volume":"77","author":"A Akcay","year":"2021","unstructured":"Akcay A, Yagci AB, Celen S, Ozlulerden Y, Turk NS, Ufuk F. VI-RADS score and tumor contact length in MRI: A potential method for the detection of muscle invasion in bladder cancer. Clin Imaging. 2021;77:25\u201336. https:\/\/doi.org\/10.1016\/j.clinimag.2021.02.026. PubMed PMID: 33639497.","journal-title":"Clin Imaging"},{"issue":"3","key":"1062_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/jmri.27090","volume":"52","author":"I Caglic","year":"2020","unstructured":"Caglic I, Panebianco V, Vargas HA, Bura V, Woo S, Pecoraro M, et al. MRI of Bladder Cancer: Local and Nodal Staging. J Magn Reson Imaging. 2020;52(3):649\u201367. https:\/\/doi.org\/10.1002\/jmri.27090. PubMed PMID: 32112505.","journal-title":"J Magn Reson Imaging"},{"issue":"7","key":"1062_CR28","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1007\/s00261-024-04788-6","volume":"50","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Xiao W, Wang Y, Zhang W, Luo M. Exploring the potential of the combined diagnostic model of ADC value and bp-MRI VI-RADS in the evaluation of muscle invasion in bladder Cancer. Abdom Radiol (NY). 2025;50(7):3100\u20137. https:\/\/doi.org\/10.1007\/s00261-024-04788-6. PubMed PMID: 39745530.","journal-title":"Abdom Radiol (NY)"},{"issue":"8","key":"1062_CR29","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s11547-022-01513-5","volume":"127","author":"M Bicchetti","year":"2022","unstructured":"Bicchetti M, Simone G, Giannarini G, Girometti R, Briganti A, Brunocilla E, et al. A novel pathway to detect muscle-invasive bladder cancer based on integrated clinical features and VI-RADS score on MRI: results of a prospective multicenter study. Radiol Med. 2022;127(8):881\u201390. https:\/\/doi.org\/10.1007\/s11547-022-01513-5. PubMed PMID: 35763251; PubMed Central PMCID: PMC9349064.","journal-title":"Radiol Med"},{"issue":"1","key":"1062_CR30","doi-asserted-by":"publisher","first-page":"e233055","DOI":"10.1148\/radiol.233055","volume":"313","author":"MA Boss","year":"2024","unstructured":"Boss MA, Malyarenko D, Partridge S, Obuchowski N, Shukla-Dave A, Winfield JM, et al. The QIBA Profile for Diffusion-Weighted MRI: Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker. Radiology. 2024;313(1):e233055. https:\/\/doi.org\/10.1148\/radiol.233055. PubMed PMID: 39377680; PubMed Central PMCID: PMC11537247.","journal-title":"Radiology"},{"issue":"2","key":"1062_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.acra.2020.10.010","volume":"29","author":"S Woo","year":"2022","unstructured":"Woo S, Ghafoor S, Becker AS, Hricak H, Goh AC, Vargas HA. Prognostic Utility of MRI Features in Intradiverticular Bladder Tumor. Acad Radiol. 2022;29(2):219\u201328. https:\/\/doi.org\/10.1016\/j.acra.2020.10.010. PubMed PMID: 33162319; PubMed Central PMCID: PMC8096867.","journal-title":"Acad Radiol"},{"key":"1062_CR32","doi-asserted-by":"publisher","unstructured":"Woo S, Luk L, Muglia VF, Briganti A, Efstathiou J, Galgano SJ, et al. VI-RADS quality score: development and proposal of a scoring system by the American College of Radiology VI-RADS Steering Committee. Eur Radiol. 2025 Aug 20. https:\/\/doi.org\/10.1007\/s00330-025-11966-7. PubMed PMID: 40830701.","DOI":"10.1007\/s00330-025-11966-7"},{"issue":"11","key":"1062_CR33","doi-asserted-by":"publisher","first-page":"7068","DOI":"10.1007\/s00330-024-10795-4","volume":"34","author":"M de Rooij","year":"2024","unstructured":"de Rooij M, Allen C, Twilt JJ, Thijssen LCP, Asbach P, Barrett T, et al. PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI. Eur Radiol. 2024;34(11):7068\u201379. https:\/\/doi.org\/10.1007\/s00330-024-10795-4. PubMed PMID: 38787428; PubMed Central PMCID: PMC11519155.","journal-title":"Eur Radiol"},{"issue":"1","key":"1062_CR34","doi-asserted-by":"publisher","first-page":"e250094","DOI":"10.1148\/rg.250094","volume":"46","author":"AS Purysko","year":"2026","unstructured":"Purysko AS, Garcia-Tomkins K, Zacharias-Andrews K, Bittencourt LK, Giganti F, Turkbey B, et al. Improving Prostate MRI: Lessons Learned from the American College of Radiology\u2019s Prostate MR Image Quality Improvement Collaborative. Radiographics. 2026;46(1):e250094. https:\/\/doi.org\/10.1148\/rg.250094. PubMed PMID: 41343296.","journal-title":"Radiographics"},{"issue":"5","key":"1062_CR35","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.eururo.2019","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi A, Bandini M, Calareso G, Raggi D, Pederzoli F, Far\u00e8 E, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol. 2020;77(5):636\u201343. https:\/\/doi.org\/10.1016\/j.eururo.2019.12.016. PubMed PMID: 31882281.","journal-title":"Eur Urol"},{"issue":"1","key":"1062_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40644-023-00632-0","volume":"23","author":"S Woo","year":"2023","unstructured":"Woo S, Becker AS, Das JP, Ghafoor S, Arita Y, Benfante N, et al. Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI. Cancer Imaging. 2023;23(1):110. https:\/\/doi.org\/10.1186\/s40644-023-00632-0. PubMed PMID: 37964386; PubMed Central PMCID: PMC10644594.","journal-title":"Cancer Imaging"},{"issue":"1","key":"1062_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.eururo.2025.03.017","volume":"89","author":"S Gupta","year":"2026","unstructured":"Gupta S, Hensley PJ, Li R, Choudhury A, Daneshmand S, Faltas BM, et al. Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Eur Urol. 2026;89(1):18\u201328. https:\/\/doi.org\/10.1016\/j.eururo.2025.03.017. PubMed PMID: 40268594.","journal-title":"Eur Urol"},{"issue":"7suppl","key":"1062_CR38","doi-asserted-by":"publisher","first-page":"LBA630","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA630","volume":"44","author":"MD Galsky","year":"2026","unstructured":"Galsky MD, Valderrama BP, Maruzzo M, Font Pous A, Ciuleanu TE, Chatzkel JA, et al. Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study. J Clin Oncol. 2026;44(7suppl):LBA630\u2013630. https:\/\/doi.org\/10.1200\/JCO.2026.44.7_suppl.LBA630.","journal-title":"J Clin Oncol"},{"issue":"7suppl","key":"1062_CR39","doi-asserted-by":"publisher","first-page":"LBA632","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA632","volume":"44","author":"P Ghatalia","year":"2026","unstructured":"Ghatalia P, Ross EA, Zibelman MR, Anari F, Abbosh P, Herberts C, et al. Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC): Integrated analysis of the RETAIN trials. J Clin Oncol. 2026;44(7suppl):LBA632\u2013632. https:\/\/doi.org\/10.1200\/JCO.2026.44.7_suppl.LBA632.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1062_CR40","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00261-021-03365-5","volume":"47","author":"M Pecoraro","year":"2022","unstructured":"Pecoraro M, Del Giudice F, Magliocca F, Simone G, Flammia S, Leonardo C, et al. Vesical Imaging-Reporting and Data System (VI-RADS) for assessment of response to systemic therapy for bladder cancer: preliminary report. Abdom Radiol (NY). 2022;47(2):763\u201370. https:\/\/doi.org\/10.1007\/s00261-021-03365-5. PubMed PMID: 34919160.","journal-title":"Abdom Radiol (NY)"},{"issue":"7","key":"1062_CR41","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1007\/s00330-024-11327","volume":"35","author":"A Dehghanpour","year":"2025","unstructured":"Dehghanpour A, Pecoraro M, Messina E, Laschena L, Borrelli A, Novelli S, et al. Diagnostic accuracy and inter-reader agreement of the nacVI-RADS for bladder cancer treated with neoadjuvant chemotherapy: a prospective validation study. Eur Radiol. 2025;35(7):4016\u201326. https:\/\/doi.org\/10.1007\/s00330-024-11327-w. PubMed PMID: 39738561.","journal-title":"Eur Radiol"},{"issue":"3","key":"1062_CR42","doi-asserted-by":"publisher","first-page":"e233020","DOI":"10.1148\/radiol.233020","volume":"313","author":"G Brembilla","year":"2024","unstructured":"Brembilla G, Basile G, Cosenza M, Giganti F, Del Prete A, Russo T, et al. Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI. Radiology. 2024;313(3):e233020. https:\/\/doi.org\/10.1148\/radiol.233020. PubMed PMID: 39718497.","journal-title":"Radiology"},{"key":"1062_CR43","doi-asserted-by":"publisher","unstructured":"Dehghanpour A, Davenport MS, Muglia VF, Nicola R, Shen L, Shinagare AB, et al. Vesical imaging reporting and data system: overcoming barriers to global implementation-AJR expert panel narrative review. AJR Am J Roentgenol. 2025 Sep 3. https:\/\/doi.org\/10.2214\/AJR.25.33634. PubMed PMID: 40899674.","DOI":"10.2214\/AJR.25.33634"},{"issue":"11","key":"1062_CR44","doi-asserted-by":"publisher","first-page":"7494","DOI":"10.1007\/s00330-022-08766-8","volume":"32","author":"MC da Silva","year":"2022","unstructured":"da Silva MC, Pecoraro M, Pisciotti ML, Dehghanpour A, Forookhi A, Lucciola S, et al. The learning curve in bladder MRI using VI-RADS assessment score during an interactive dedicated training program. Eur Radiol. 2022;32(11):7494\u2013503. https:\/\/doi.org\/10.1007\/s00330-022-08766-8. PubMed PMID: 35366122; PubMed Central PMCID: PMC8976109.","journal-title":"Eur Radiol"},{"key":"1062_CR45","doi-asserted-by":"publisher","first-page":"110279","DOI":"10.1016\/j.clinimag.2024.110279","volume":"114","author":"N Gunduz","year":"2024","unstructured":"Gunduz N, Dogan MB, Kazan HO, Culpan M, Y\u0131ld\u0131r\u0131m A, Erdem G. Effect of accumulating experience on diagnostic performance of VI-RADS in bladder cancer. Clin Imaging. 2024;114:110279. https:\/\/doi.org\/10.1016\/j.clinimag.2024.110279. PubMed PMID: 39241573.","journal-title":"Clin Imaging"},{"key":"1062_CR46","unstructured":"UROwebinar. MRI in Bladder cancer. https:\/\/uroweb.org\/education-events\/urowebinar-mri-in-bladder-cancer. Accessed 15 January 2026."},{"key":"1062_CR47","unstructured":"European Soceity of Urogenital Radiology. 2023 Symposium. https:\/\/areasoci.sirm.org\/uploads\/Corsi\/Volantini\/bee71a4dc25f070395a23992d03f6a0cae9b62dd.pdf. Page 15. Accessed 15 January 2026."},{"issue":"11","key":"1062_CR48","doi-asserted-by":"publisher","first-page":"7513","DOI":"10.1007\/s00330-022-08813-4","volume":"32","author":"M Watanabe","year":"2022","unstructured":"Watanabe M, Taguchi S, Machida H, Tambo M, Takeshita Y, Kariyasu T, et al. Clinical validity of non-contrast-enhanced VI-RADS: prospective study using 3-T MRI with high-gradient magnetic field. Eur Radiol. 2022;32(11):7513\u201321. https:\/\/doi.org\/10.1007\/s00330-022-08813-4. PubMed PMID: 35554648; PubMed Central PMCID: PMC9668777.","journal-title":"Eur Radiol"},{"issue":"13","key":"1062_CR49","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.3390\/cancers16132348","volume":"16","author":"KZ Gumus","year":"2024","unstructured":"Gumus KZ, Nicolas J, Gopireddy DR, Dolz J, Jazayeri SB, Bandyk M. Deep Learning Algorithms for Bladder Cancer Segmentation on Multi-Parametric MRI. Cancers (Basel). 2024;16(13):2348. https:\/\/doi.org\/10.3390\/cancers16132348. PubMed PMID: 39001410; PubMed Central PMCID: PMC11240435.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1062_CR50","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/bioengineering12121338","volume":"12","author":"M Song","year":"2025","unstructured":"Song M, Ren H, Wang L, Zhou Y, Tang X, Wang H, et al. Beyond VI-RADS Uncertainty: Leveraging Spatiotemporal DCE-MRI to Predict Bladder Cancer Muscle Invasion. Bioeng (Basel). 2025;12(12):1338. https:\/\/doi.org\/10.3390\/bioengineering12121338. PubMed PMID: 41463635; PubMed Central PMCID: PMC12729362.","journal-title":"Bioeng (Basel)"},{"issue":"4","key":"1062_CR51","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1007\/s00330-022-09272-7","volume":"33","author":"J Li","year":"2023","unstructured":"Li J, Cao K, Lin H, Deng L, Yang S, Gao Y, et al. Predicting muscle invasion in bladder cancer by deep learning analysis of MRI: comparison with vesical imaging-reporting and data system. Eur Radiol. 2023;33(4):2699\u2013709. https:\/\/doi.org\/10.1007\/s00330-022-09272-7. PubMed PMID: 36434397.","journal-title":"Eur Radiol"},{"key":"1062_CR52","doi-asserted-by":"publisher","unstructured":"Al-Sattar H, Ding H, Okoli O, Okoli S, Ghose A, Banna GL, et al. A multi-modal approach for decision making in bladder cancer. Nat Rev Urol. 2026 Jan 14. https:\/\/doi.org\/10.1038\/s41585-025-01122-7. PubMed PMID: 41535603.","DOI":"10.1038\/s41585-025-01122-7"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01062-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01062-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01062-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:22:38Z","timestamp":1785806558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01062-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1062"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01062-4","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable in the review article.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"97"}}